{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:46:42Z","timestamp":1789213602402,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ijrobp.2021.06.032","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T10:59:07Z","timestamp":1625309947000},"page":"917-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial"],"prefix":"10.1016","volume":"111","author":[{"given":"Bo","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaQuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiWen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YingJia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SuPing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoBo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianLan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinYu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FangJie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiMei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongHong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-3756","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.06.032_bib0001","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/annonc\/mdx009","article-title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: A multicenter randomized phase III trial","volume":"28","author":"Liang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0002","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0004","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0005","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0007","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.str.2007.11.009","article-title":"Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8","volume":"16","author":"Li","year":"2008","journal-title":"Structure"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0008","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ijc.10647","article-title":"Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody","volume":"101","author":"Crombet-Ramos","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0009","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fonc.2020.00817","article-title":"Nimotuzumab for patients with inoperable cancer of the head and neck","volume":"10","author":"Crombet Ramos","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0010","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.18632\/oncotarget.13899","article-title":"Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: Preliminary results from a phase II clinical trial","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0011","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/cncr.32179","article-title":"A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer","volume":"125","author":"Patil","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0012","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.bjc.6604222","article-title":"Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status","volume":"98","author":"Akashi","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2006.08.015","article-title":"Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer","volume":"54","author":"Jeon","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0014","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/annonc\/mdw214","volume":"27","author":"Paz-Ares","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2010.04.010","article-title":"A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results","volume":"71","author":"Choi","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0017","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13014-020-01555-x","volume":"15","author":"Qiu","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0018","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.07.3569","article-title":"Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and leukemia group B","volume":"25","author":"Vokes","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0019","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1200\/JCO.2010.31.7875","article-title":"Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA\/B non-small-cell lung cancer: RTOG 0324","volume":"29","author":"Blumenschein","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0020","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0021","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijrobp.2014.02.025","article-title":"Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation","volume":"89","author":"Ji","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0023","doi-asserted-by":"crossref","first-page":"C181","DOI":"10.4103\/0973-1482.200596","article-title":"Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer","volume":"12","author":"Ju","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0024","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2147\/OTT.S230399","article-title":"Dual targeting of the epidermal growth factor receptor using combination of nimotuzumab and erlotinib in advanced non-small-cell lung cancer with leptomeningeal metastases: A report of three cases","volume":"13","author":"Xu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0025","first-page":"59","article-title":"Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer","volume":"2","author":"Takeda","year":"2011","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0026","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fphar.2017.00382","article-title":"Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients","volume":"8","author":"Mazorra","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0027","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","article-title":"Nimotuzumab: Beyond the EGFR signaling cascade inhibition","volume":"45","author":"Mazorra","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0028","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0029","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1158\/0008-5472.CAN-08-4518","article-title":"Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation","volume":"69","author":"Talavera","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0031","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1200\/JCO.2020.38.15_suppl.9039","article-title":"Real-world survey of pneumonitis\/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval: A multicenter retrospective cohort study (HOPE-005\/CRIMSON)","volume":"38","author":"Saito","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0032","doi-asserted-by":"crossref","first-page":"9034","DOI":"10.1200\/JCO.2020.38.15_suppl.9034","article-title":"Evaluation of the incidence of pneumonitis in United States veterans with non-small cell lung cancer receiving durvalumab following chemoradiation","volume":"38","author":"Thomas","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0033","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.1016\/j.jtho.2018.08.237","article-title":"OA01.06 DETERRED: Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer","volume":"13","author":"Lin","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.032_bib0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer\u2014The ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621008245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621008245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:54:04Z","timestamp":1759744444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621008245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0360301621008245"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.032","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}